Data on mRNA vaccines sent by Moderna to European regulators before the COVID-19 outbreak included early tests of the mRNA ...
Nanoparticle characterization is vital for mRNA vaccine efficacy, ensuring safety and regulatory compliance in the ...
A member of the U.K. Parliament is calling for regulators to audit pharmaceutical companies that have made misleading ...
A trial of Moderna’s norovirus vaccine in the U.S. has been put on hold by the FDA over a reported case of neurological ...
MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...
Pfizer’s two-year run with the only 5-in-1 meningococcal vaccine on the U.S. market has come to an end. Now, GSK is ready to ...
Moderna (MRNA), once a pandemic-era darling, has seen its stock plummet 65% over the past year, battered by fading vaccine ...